Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALE.P02 alone or with pembrolizumab in CLDN1-positive squamous solid tumors
NL-OMON61634Phase 2Recruiting
- Sponsor
- Alentis Therapeutics
- Start
- Oct 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of ALE.P02 in Pulmonary squamous cell carcinoma, head and neck squamous cell carcinoma (HNSCC), Esophageal Squamous Cell Carcinoma (ESCC) and 1 more (2 arms), sponsored by Alentis Therapeutics. Primary endpoints: Dose-limiting toxicities, Safety and adverse events and 4 more. Started Oct 2026; status: recruiting.
02
Drugs
ALE.P02
03
Conditions
Pulmonary squamous cell carcinomahead and neck squamous cell carcinoma (HNSCC)Esophageal Squamous Cell Carcinoma (ESCC)cervical squamous cell carcinoma (CSCC)
Beyond the preview
Go deeper on NL-OMON61634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61634.